Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TVM Capital and Chongqing Lummy Pharma Form China In-Licensing Fund

publication date: Apr 13, 2015
TVM Capital Life Science of Germany closed the first tranche of its China BioPharma Capital I fund at $50 Million, with Chongqing Lummy Pharma the strategic partner and apparently the only investor. The Capital I fund will seek to in-license China rights to innovative drugs and medical devices from Western companies, which Lummy will bring to China's market. TVM Capital Life Science describes itself as a group of independent investment advisors and fund managers with offices in Munich, Montreal and, now with the new emphasis, Hong Kong. More details....

Stock Symbol: (SHZ: 300006)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital